Literature DB >> 16123497

Glucose-lowering effects of sulfasalazine in type 2 diabetes.

Romana M Haas1, Phoebe Li, James W Chu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123497     DOI: 10.2337/diacare.28.9.2238

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  5 in total

Review 1.  Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.

Authors:  Marco Infante; Nathalia Padilla; Rodolfo Alejandro; Massimiliano Caprio; David Della-Morte; Andrea Fabbri; Camillo Ricordi
Journal:  Medicina (Kaunas)       Date:  2022-04-21       Impact factor: 2.948

Review 2.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

3.  Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis.

Authors:  Patrick R Wood; Evan Manning; Joshua F Baker; Bryant England; Lisa Davis; Grant W Cannon; Ted R Mikuls; Liron Caplan
Journal:  World J Diabetes       Date:  2018-02-15

4.  Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study.

Authors:  So Hye Nam; Minju Kim; Ye-Jee Kim; Soo Min Ahn; Seockchan Hong; Chang-Keun Lee; Bin Yoo; Ji-Seon Oh; Yong-Gil Kim
Journal:  J Clin Med       Date:  2022-04-10       Impact factor: 4.964

Review 5.  Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review.

Authors:  Giacomo Dal Bello; Paolo Gisondi; Luca Idolazzi; Giampiero Girolomoni
Journal:  Rheumatol Ther       Date:  2020-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.